MCID: NRC002
MIFTS: 62

Narcolepsy malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Narcolepsy

About this section
Sources:
11Disease Ontology, 13DISEASES, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Narcolepsy:

Name: Narcolepsy 11 48 25 49 50 39 13 68
Narcolepsy-Cataplexy Syndrome 48 54 27 68
Narcoleptic Syndrome 48 25
Gelineau Syndrome 48 25
Paroxysmal Sleep 11 48
 
Narcolepsy, Without Cataplexy 11
Narcolepsy Without Cataplexy 54
Gelineau's Syndrome 48
Gélineau Disease 54

Characteristics:

Orphanet epidemiological data:

54
narcolepsy-cataplexy syndrome:
Prevalence: 1-5/10000 (Europe),1-5/10000 (Norway),1-5/10000 (Finland),1-5/10000 (China); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy
narcolepsy without cataplexy:
Prevalence: 1-5/10000 (United States); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:8986
ICD9CM32 347.0
MeSH39 D009290
NCIt45 C84489
ICD10 via Orphanet31 G47.4
MESH via Orphanet40 D009290
UMLS via Orphanet69 C0027404, C0751362

Summaries for Narcolepsy

About this section
NINDS:49 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleeep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience irresistable bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms ofcataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis . The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

MalaCards based summary: Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to narcolepsy 1 and cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, and has symptoms including hemiplegia, sleep disturbances and excessive daytime somnolence. An important gene associated with Narcolepsy is HCRT (Hypocretin Neuropeptide Precursor), and among its related pathways are Translocation of ZAP-70 to Immunological synapse and CTLA4 Signaling. The drugs amphetamine adipate and dextroamphetamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and testes, and related mouse phenotype nervous system.

Disease Ontology:11 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference:25 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NIH Rare Diseases:48 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. people with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). the disorder is usually sporadic but some cases are familial. there is no cure, but some symptoms can be managed with medicines and lifestyle changes. last updated: 4/27/2015

Wikipedia:71 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

About this section

Diseases in the Narcolepsy family:

Narcolepsy 2 Narcolepsy 7
Narcolepsy 5 Narcolepsy 1
Narcolepsy 6 Narcolepsy 3
Narcolepsy 4 Narcolepsy Risk Factor

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 115)
idRelated DiseaseScoreTop Affiliating Genes
1narcolepsy 112.4
2cerebellar ataxia, deafness, and narcolepsy, autosomal dominant12.2
3narcolepsy 712.2
4narcolepsy 211.9
5narcolepsy 311.8
6narcolepsy 511.8
7narcolepsy 611.8
8narcolepsy 411.8
9narcolepsy risk factor11.7
10idiopathic hypersomnia11.3
11hypersomnia11.3
12sleep disorder11.2
13imaizumi kuroki syndrome10.4HCRT, HLA-DQB1
14autosomal dominant intermediate charcot-marie-tooth10.4HLA-DQB1, HLA-DRB1, TNF
15rud syndrome10.4HCRT, HCRTR1, HCRTR2
16distal trisomy 14q10.4HLA-DQB1, HLA-DRB1, TNF
17hemoglobin d disease10.4HLA-DQA1, HLA-DQB1, HLA-DRB1
18clostridium difficile colitis10.4HLA-DQB1, HLA-DRB1, TNF
19osteogenesis imperfecta congenita, microcephaly, and cataracts10.4HLA-DQA1, HLA-DQB1
20cryptococcosis10.4HLA-DQB1, HLA-DRB1, TNF
21myopathy, distal, with early respiratory failure, autosomal dominant10.4COMT, HCRT, HLA-DQB1
22oromandibular dystonia10.4HLA-DQA1, HLA-DQB1, HLA-DRB1
23migraine with aura10.4HLA-DQA1, HLA-DQB1, TNF
24kernicterus due to isoimmunization10.4HLA-DQA1, HLA-DRB1, TNF
25bickerstaff brainstem encephalitis10.4HLA-DQA1, HLA-DQB1, HLA-DRB1
26niemann-pick disease10.4HCRT, HLA-DRB1, MOG
27low anorectal malformation10.4HLA-DQB1, HLA-DRB1, TNF
28choreatic disease10.4HCRT, HLA-DQB1, HLA-DRB1, TNF
29hodgkin's paragranuloma10.4HCRT, HLA-DQB1
30lyme disease - neurological complications10.4HCRT, HCRTR1, HLA-DQB1, HLA-DRB1
31ragweed sensitivity10.4HLA-DQA1, HLA-DQB1, HLA-DRB1
32parasitic helminthiasis infectious disease10.4HLA-DQB1, HLA-DRB1, MOG, TNF
33infantile hypotonia10.4HCRTR2, HLA-DQB1, TNF
34apple allergy10.4HLA-DQB1, HLA-DRB1
35bilateral parasagittal parieto-occipital polymicrogyria10.4HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
36pulmonary hemosiderosis10.4HLA-DRB1, MOG, TNF
37peripheral artery disease10.4HLA-DQA1, HLA-DRB1, TNF
38cervical adenoid basal carcinoma10.4HCRT, HLA-DQA1, HLA-DQB1, HLA-DRB1, MOG
39nystagmus, congenital motor, autosomal recessive10.4HLA-DRB1, LEP, TNF
40immune deficiency, familial variable10.4HLA-DQB1, HLA-DRB1
41advanced sleep phase syndrome, familial, 110.4HLA-DQB1, HLA-DRB1, MOG, TNF
42epithelioid type angiomyolipoma10.4ATXN3, HCRT, MOG, TNF
43limb ischemia10.4HCRT, LEP, TNF
44diabetic encephalopathy10.3HCRT, LEP, TNF
45lin-gettig syndrome10.3HLA-DQB1, HLA-DRB1
46breast hemangiopericytoma10.3HCRT, HCRTR1, HCRTR2, LEP, MOG
47erythematosquamous dermatosis10.3HLA-DQB1, HLA-DRB1, TNF
48mirizzi syndrome10.3HLA-DRB1, TNF
49t-cell prolymphocytic leukemia10.3HLA-DQB1, TNF
50midline interhemispheric variant of holoprosencephaly10.3HLA-DQB1, HLA-DRB1

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, EssentialHypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to narcolepsy

Symptoms & Phenotypes for Narcolepsy

About this section

Human phenotypes related to Narcolepsy:

 54 64 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the eye54 Frequent (79-30%)
2 abnormality of vision64 54 Frequent (79-30%) HP:0000504
3 hallucinations64 54 Very frequent (99-80%) HP:0000738
4 syncope64 54 Occasional (29-5%) HP:0001279
5 slurred speech64 54 Occasional (29-5%) HP:0001350
6 obesity64 54 Occasional (29-5%) HP:0001513
7 excessive daytime sleepiness64 54 Very frequent (99-80%) HP:0002189
8 sleep disturbance54 Very frequent (99-80%)
9 abnormal rapid eye movement (rem) sleep54 Frequent (79-30%)
10 cataplexy64 54 Very frequent (99-80%) HP:0002524
11 transient global amnesia64 54 Very frequent (99-80%) HP:0010534
12 behavioral abnormality54 Occasional (29-5%)
13 somnolence54 Very frequent (99-80%)
14 insomnia64 54 Very frequent (99-80%) HP:0100785
15 abnormal rapid eye movement sleep64 HP:0002494
16 excessive daytime somnolence64 HP:0001262

UMLS symptoms related to Narcolepsy:


hemiplegia, sleep disturbances, excessive daytime somnolence, sleeplessness, sluggishness

MGI Mouse Phenotypes related to Narcolepsy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036319.6ATXN3, COMT, DNMT1, HCRT, HCRTR1, HCRTR2

Drugs & Therapeutics for Narcolepsy

About this section

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 103)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Modafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 119768693-11-84236
Synonyms:
2-((diphenylmethyl)sulfinyl)acetamide
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
 
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
2
Armodafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1197112111-43-0
Synonyms:
 
(–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
R-modafinil
3
Sodium oxybateapprovedPhase 4, Phase 3, Phase 2, Phase 138502-85-25360545
Synonyms:
4-Hydroxybuttersaeure natriumsalz
4-Hydroxybutyrate sodium
4-Hydroxybutyric acid monosodium salt
4-Hydroxybutyric acid sodium salt
502-85-2
ARONIS24196
Anetamin
BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT
Butanoic acid, 4-hydroxy-, monosodium salt
Butanoic acid, 4-hydroxy-, sodium salt
Butanoic acid, 4-hydroxy-, sodium salt (1:1)
Butyric acid, 4-hydroxy-, monosodium salt
Butyric acid, 4-hydroxy-, monosodium salt (8CI)
C4H7O3.Na
CHEMBL1200682
CID10412
D05866
EB 27
EINECS 207-953-3
GHB
Gamma OH
H-4040
H3635_SIGMA
HMS2091E15
Hydroxybutyric acid monosodium salt
 
LS-48077
MolPort-001-766-711
MolPort-006-717-541
NSC 84223
Natrium 4-hydroxybutyrat
OR28769
Oxybate sodium
Sodium 4-hydroxybutyrate
Sodium Oxybate [USAN]
Sodium Oxybutyrate
Sodium gamma-hydroxybutyrate
Sodium gammahydroxybutyrate
Sodium oxybate
Sodium oxybate (USAN)
Sodium-4-hydroxybutyrate
Somsanit
UNII-7G33012534
WY 3478
WY-3478
Xyrem
Xyrem (TN)
gamma-Hydroxy sodium butyrate
gamma-Hydroxybutyrate sodium
gamma-Hydroxybutyrate sodium salt
gamma-Hydroxybutyric acid sodium salt
gamma-Hydroxybutyric acid, sodium salt
4
DopamineapprovedPhase 4, Phase 2, Phase 3, Phase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
5
Gabapentinapproved, investigationalPhase 430360142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
6
RasagilineapprovedPhase 454136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
7
Pramipexoleapproved, investigationalPhase 4139104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
8
RibavirinapprovedPhase 4100336791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
9Wakefulness-Promoting AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1193
10Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
11Central Nervous System StimulantsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12211
12Cytochrome P-450 CYP3A InducersPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11119
13Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 113403
14AnalgesicsPhase 4, Phase 3, Phase 1, Phase 211733
15Psychotropic DrugsPhase 46430
16Anti-Anxiety AgentsPhase 41885
17Tranquilizing AgentsPhase 44265
18Adjuvants, AnesthesiaPhase 4, Phase 3, Phase 2, Phase 11674
19Autonomic AgentsPhase 4, Phase 2, Phase 110150
20Anesthetics, IntravenousPhase 4, Phase 3, Phase 2, Phase 12538
21Anesthetics, GeneralPhase 4, Phase 3, Phase 2, Phase 12934
22AnestheticsPhase 4, Phase 3, Phase 2, Phase 19596
23Pharmaceutical SolutionsPhase 4, Phase 38192
24VaccinesPhase 46611
25Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 118340
26Dopamine AgentsPhase 4, Phase 2, Phase 3, Phase 13836
27Protective AgentsPhase 4, Phase 1, Phase 27443
28AnticonvulsantsPhase 42695
29Antiparkinson AgentsPhase 41574
30calcium channel blockersPhase 41985
31Excitatory Amino AcidsPhase 41362
32Antimanic AgentsPhase 4814
33Calcium, DietaryPhase 4, Phase 1, Phase 25713
34Excitatory Amino Acid AntagonistsPhase 41347
35Neuroprotective AgentsPhase 41716
36Dopamine agonistsPhase 4632
37Interferon-alphaPhase 41152
38AntioxidantsPhase 43050
39interferonsPhase 42175
40
Morphineapproved, investigationalPhase 3100757-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
41
Histamineapproved, investigationalPhase 3, Phase 2105075614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-(4-imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
4-imidazoleethylamine
5-Imidazoleethylamine
5-imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminoethylglyoxaline
beta-aminoethylimidazole
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
42
Methylphenidateapproved, investigationalPhase 2, Phase 3375113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
43
Folic Acidapproved, nutraceutical, vet_approvedPhase 3439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
44
Pyridoxineapproved, nutraceutical, vet_approvedPhase 318865-23-61054
Synonyms:
(5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate
12001-78-4
2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine
2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine
2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-methyl-4,5-dimethylol-pyridin-3-ol
2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0
3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride
3-Hydroxy-2-Picoline-4,5-dimethanol
3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride
3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-alpha-picoline
3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride
4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol
4-Deoxypyridoxine 5'-phosphate
47862_SUPELCO
5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
58-56-0
58-56-0 (HCL)
58-56-0 (hydrochloride)
65-23-6
65-23-6 (Parent)
8059-24-3
85078-23-5
AC-12024
AC-14512
AC-907/25014218
AC1L1AMH
AC1L1LMI
AC1L2XK2
AC1Q22HP
AC1Q2G66
AC1Q3F63
AI3-19016
AIDS-006784
AIDS006784
AR-1A6363
AR-1J1632
Adermin hydrochloride
Adermine
Adermine hydrochloride
Aderomine hydrochloride
Aderoxin
Aderoxine
Alestrol
BB_NC-0050
BIDD:PXR0180
BPBio1_000646
BSPBio_000586
Becilan
Beesix
Benadon
Bonasanit
C00314
C8H11NO3
CAS-58-56-0
CBDivE_015627
CCRIS 1903
CHEBI:16709
CHEBI:30961
CHEMBL1200756
CHEMBL1364
CID104817
CID1054
CID6019
CPD0-1221
Campoviton 6
Cernevit-12
D02179
D025101
D08454
DB00165
EINECS 200-386-2
EINECS 200-603-0
EINECS 232-503-8
Godabion
Gravidox
HMS1569N08
HMS2093L07
HSDB 1212
Hexa-Betalin
Hexa-Betalin (R)
Hexa-betalin (TN)
Hexabetalin
Hexabione hydrochloride
 
Hexavibex
Hexermin
Hexermine
Hexobion
Hydoxin
I02-1897
I02-2297
KST-1A8556
LS-134393
LS-187072
LS-2332
MLS001074329
MLS002153915
MolPort-002-137-856
MolPort-002-319-991
MolPort-005-933-330
NCGC00016261-01
NCGC00164317-01
NCGC00180946-01
NSC 36225
NSC36225
NSC36225 (HCL)
Nestrex
Oprea1_061614
P0561
P4722_SIAL
P5669_SIGMA
P6280_SIGMA
P8666_SIGMA
P9755_SIAL
PN
PN HCl
PYRIDOXINE HYDROCHLORIDE
PYRIDOXINE HYDROCHLORIDE, U.S.P.
Paxadon
Piridossina
Piridossina [DCIT]
Piridoxina
Piridoxina [INN-Spanish]
Prestwick0_000623
Prestwick1_000623
Prestwick2_000623
Prestwick3_000623
Prestwick_925
Pydox
Pyridipca
Pyridox
Pyridoxin
Pyridoxin hydrochloride
Pyridoxine
Pyridoxine (INN)
Pyridoxine HCl
Pyridoxine Hydrochloride (B6)
Pyridoxine [INN:BAN]
Pyridoxine chloride
Pyridoxine hydrochloride (JP15/USP)
Pyridoxine hydrochloride [USAN:JAN]
Pyridoxine hydrogen chloride
Pyridoxine monohydrochloride
Pyridoxine, hydrochloride
Pyridoxine-HCl Microencapsulated
Pyridoxinium chloride
Pyridoxinum
Pyridoxinum [INN-Latin]
Pyridoxinum hydrochloricum
Pyridoxinum hydrochloricum (Hungarian)
Pyridoxol
Pyridoxol hydrochloride
Pyridoxol, hydrochloride
Pyridoxolum
Rodex
Rodex (R)
Rodex TD
SMP2_000230
SMR000674613
SPBio_002805
STK177324
STOCK1N-08684
Spondylonal
Tex Six T.R.
TimTec1_000657
UNII-68Y4CF58BV
UNII-KV2JZ1BI6Z
Vitamin B 6
Vitamin B6
Vitamin B6-hydrochloride
Vitamin V6
Vitamin V6 (TN)
Vitamin-?B6
Vitamin-?B6 hydrochloride
Vitaped
WLN: T6NJ B1 CQ D1Q E1Q &GH
ZINC00049154
ZINC21983293
bmse000288
c1302
component of Alestrol
nchembio.93-comp1
pyridoxine
vitamin B6
45
Pyridoxalapproved, nutraceuticalPhase 318766-72-81050
Synonyms:
2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine
3-Hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde
 
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde
3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
Piridoxal
Pyridoxal
Pyridoxaldehyde
46NarcoticsPhase 33646
47Analgesics, OpioidPhase 33238
48Trace ElementsPhase 36001
49Vitamin B ComplexPhase 34337
50Dopamine Uptake InhibitorsPhase 2, Phase 3, Phase 11331

Interventional clinical trials:

(show top 50)    (show all 93)
idNameStatusNCT IDPhase
1Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine ChangesCompletedNCT00345800Phase 4
2Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on PrescriptionCompletedNCT00244465Phase 4
3Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDSCompletedNCT00118378Phase 4
4An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia FatigueCompletedNCT00678691Phase 4
5"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"CompletedNCT01023672Phase 4
6SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)CompletedNCT02055898Phase 4
7Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
8Xyrem and Brain Dopamine in NarcolepsyRecruitingNCT02637076Phase 4
9Pain Expectations in Subjects With OsteoarthritisRecruitingNCT02155257Phase 4
10Modafinil Treatment for Sleep/Wake Disturbances in Older AdultsTerminatedNCT00626210Phase 4
11Armodafinil for Patients Starting Hepatitis C Virus TreatmentTerminatedNCT01470651Phase 4
12Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseTerminatedNCT01048229Phase 4
13Palliative Morphine With or Without Concurrent ModafinilUnknown statusNCT01766323Phase 3
14Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With NarcolepsyCompletedNCT00107796Phase 3
15Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in NarcolepsyCompletedNCT00066170Phase 3
16Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.CompletedNCT01638403Phase 3
17PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107848Phase 3
18Trial of Xyrem® (Sodium Oxybate) for the Treatment of NarcolepsyCompletedNCT00132873Phase 3
19Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NarcolepsyCompletedNCT00078377Phase 3
20Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)CompletedNCT01399606Phase 3
21Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderCompletedNCT00078312Phase 3
22Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic PatientsCompletedNCT00049803Phase 3
23Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessCompletedNCT00228553Phase 3
24Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive SleepinessCompletedNCT00214968Phase 3
25Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in NarcolepsyCompletedNCT01067222Phase 3
26Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00228566Phase 3
27Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With NarcolespyCompletedNCT01067235Phase 3
28Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)CompletedNCT01789398Phase 3
29Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)CompletedNCT01800045Phase 3
30Methylphenidate to Improve Balance and Walking in MSCompletedNCT01896700Phase 2, Phase 3
31Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese PatientsCompletedNCT02478580Phase 3
32Modafinil in Cancer Related FatigueCompletedNCT01440621Phase 3
33Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyRecruitingNCT02720744Phase 3
34A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With CataplexyRecruitingNCT03030599Phase 3
35"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"Active, not recruitingNCT02348593Phase 3
36A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With CataplexyActive, not recruitingNCT02221869Phase 3
37"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"Active, not recruitingNCT02348606Phase 3
38"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"Enrolling by invitationNCT02348632Phase 3
39Modafinil to Treat Fatigue in Post-Polio SyndromeTerminatedNCT00067496Phase 3
40A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With NarcolepsyCompletedNCT00424931Phase 2
41A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With NarcolepsyCompletedNCT01681121Phase 2
42A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With NarcolepsyCompletedNCT01006122Phase 2
43A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime SleepinessCompletedNCT01485770Phase 2
44Clarithromycin for the Treatment of HypersomniaCompletedNCT01146600Phase 2
45Flumazenil for the Treatment of Primary HypersomniaCompletedNCT01183312Phase 1, Phase 2
46Methylphenidate and Parkinson's DiseaseCompletedNCT00359723Phase 2
47Sodium Oxybate in Schizophrenia With InsomniaCompletedNCT00594256Phase 2
48Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse HistoriesCompletedNCT00247572Phase 2
49Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant AbuseCompletedNCT00248092Phase 1, Phase 2
50Modafinil vs Placebo for the Treatment of Methamphetamine DependenceCompletedNCT00469508Phase 2

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

About this section

Genetic tests related to Narcolepsy:

id Genetic test Affiliating Genes
1 Cataplexy and Narcolepsy27

Anatomical Context for Narcolepsy

About this section

MalaCards organs/tissues related to Narcolepsy:

36
Brain, Eye, Testes, T cells, Amygdala, Heart, Skin

Publications for Narcolepsy

About this section

Articles related to Narcolepsy:

(show top 50)    (show all 822)
idTitleAuthorsYear
1
Perioperative risks of narcolepsy in patients undergoing general anesthesia: A case-control study. (28433385)
2017
2
Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy. (28364500)
2017
3
Pituitary Macrotumor Causing Narcolepsy-Cataplexy in a Dachshund. (28090682)
2017
4
Update on the treatment of narcolepsy: clinical efficacy of pitolisant. (28490912)
2017
5
Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. (28522102)
2017
6
New developments in the management of narcolepsy. (28424564)
2017
7
Rare missense mutations in P2RY11 in narcolepsy with cataplexy. (28460015)
2017
8
Sleep-wake patterns, non-rapid eye movement, and rapid eye movement sleep cycles in teenage narcolepsy. (28449905)
2017
9
The spectrum of REM sleep-related episodes in children with type 1 narcolepsy. (28472332)
2017
10
Comorbidity of narcolepsy with cataplexy and transverse myelitis: aA common autoimmune background? A case report. (28449899)
2017
11
Sleep-wake stability in narcolepsy patients with normal, low and unmeasurable hypocretin levels. (28522076)
2017
12
Cardiovascular fitness in narcolepsy is inversely related to sleepiness and the number of cataplexy episodes. (28522101)
2017
13
Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: a review of current patient-reported measures. (28366326)
2017
14
Narcolepsy drug could help food addicts lose weight. (28075285)
2017
15
Sleep spindle density in narcolepsy. (28522097)
2017
16
Irish MP calls for key documents on Pandemrix to be handed to lawyers representing children with narcolepsy. (28428181)
2017
17
Spectral electroencephalography profile of rapid eye movement sleep at sleep onset in narcolepsy type 1. (27905666)
2017
18
Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. (28449892)
2017
19
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. (27995691)
2017
20
a91Pitolisant for narcolepsy. (28087755)
2017
21
Pharmacological management of narcolepsy with and without cataplexy. (28443381)
2017
22
Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2A years of follow-up. (27995693)
2017
23
The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. (28449891)
2017
24
Rewiring brain circuits to block cataplexy in murine models of narcolepsy. (28445807)
2017
25
Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. (28507129)
2017
26
Nocturnal Dynamics of Sleep-Wake Transitions in Patients With Narcolepsy. (28364512)
2017
27
Narcolepsy Following Yellow Fever Vaccination: A Case Report. (27559330)
2016
28
Diagnostic delay in narcolepsy type 1: combining the patients' and the doctors' perspectives. (27149919)
2016
29
Psychosocial Profile and Quality of Life in Children With Type 1 Narcolepsy: A Case-Control Study. (27166243)
2016
30
Post Tick-Borne Encephalitis Virus Vaccination Narcolepsy with Cataplexy. (27397572)
2016
31
Environmental factors in the etiology of type 1 diabetes, celiac disease, and narcolepsy. (27411439)
2016
32
CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. (27621438)
2016
33
Mechanistic insights into influenza vaccine-associated narcolepsy. (27031682)
2016
34
Altered Brain Microstate Dynamics in Adolescents with Narcolepsy. (27536225)
2016
35
Autoantibody targets in vaccine-associated narcolepsy. (27206786)
2016
36
A systematic review of cognitive function and psychosocial well-being in school-age children with narcolepsy. (28065388)
2016
37
Hypocretin-1 Levels Associate with Fragmented Sleep in Patients with Narcolepsy Type 1. (26856902)
2016
38
Circadian Rest-Activity Rhythm in Pediatric Type 1 Narcolepsy. (27091539)
2016
39
Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1. (26757307)
2016
40
A Global View on Narcolepsy - A Review Study. (27488584)
2016
41
Narcolepsy with cataplexy in a child with Charcot-Marie-Tooth disease. Case Report. (27857041)
2016
42
Improved vigilance after sodium oxybate treatment in narcolepsy: a comparison between in-field and in-laboratory measurements. (26909768)
2016
43
Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. (27647645)
2016
44
Disrupted Sleep in Narcolepsy: Exploring the Integrity of Galanin Neurons in the Ventrolateral Preoptic Area. (26951397)
2016
45
Temporal changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. (27634795)
2016
46
Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis. (27143278)
2016
47
Efficiency of a Combination of Pharmacological Treatment and Nondrug Interventions in Childhood Narcolepsy. (27564079)
2016
48
Autosomal Dominant Cerebellar Ataxia, Deafness, and Narcolepsy (ADCA-DN) Associated With Progressive Cognitive and Behavioral Deterioration. (27869457)
2016
49
Narcolepsy and influenza vaccination-the inappropriate awakening of immunity. (27867997)
2016
50
Clinical course of H1N1-vaccine-related narcolepsy. (27198942)
2016

Variations for Narcolepsy

About this section

Copy number variations for Narcolepsy from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
117730935514702955255377InsertionHCRTR2Narcolepsy

Expression for genes affiliated with Narcolepsy

About this section
Search GEO for disease gene expression data for Narcolepsy.

Pathways for genes affiliated with Narcolepsy

About this section

GO Terms for genes affiliated with Narcolepsy

About this section

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1clathrin-coated endocytic vesicle membraneGO:003066910.9HLA-DQA1, HLA-DQB1, HLA-DRB1
2endocytic vesicle membraneGO:003066610.9HLA-DQA1, HLA-DQB1, HLA-DRB1
3ER to Golgi transport vesicle membraneGO:001250710.8HLA-DQA1, HLA-DQB1, HLA-DRB1
4integral component of lumenal side of endoplasmic reticulum membraneGO:007155610.8HLA-DQA1, HLA-DQB1, HLA-DRB1
5MHC class II protein complexGO:004261310.8HLA-DQA1, HLA-DQB1, HLA-DRB1
6trans-Golgi network membraneGO:003258810.7HLA-DQA1, HLA-DQB1, HLA-DRB1
7transport vesicle membraneGO:003065810.3HLA-DQA1, HLA-DQB1, HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1humoral immune response mediated by circulating immunoglobulinGO:000245511.0HLA-DQB1, HLA-DRB1
2immunoglobulin production involved in immunoglobulin mediated immune responseGO:000238111.0HLA-DQB1, HLA-DRB1
3antigen processing and presentation of exogenous peptide antigen via MHC class IIGO:001988611.0HLA-DQA1, HLA-DQB1, HLA-DRB1
4antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:000250411.0HLA-DQA1, HLA-DQB1, HLA-DRB1
5feeding behaviorGO:000763111.0HCRT, HCRTR1, HCRTR2
6leukocyte tethering or rollingGO:005090110.9LEP, TNF
7negative regulation of glucose importGO:004632510.9LEP, TNF
8negative regulation of lipid storageGO:001088810.9LEP, TNF
9antigen processing and presentationGO:001988210.9CTSH, HLA-DQA1, HLA-DQB1, HLA-DRB1
10interferon-gamma-mediated signaling pathwayGO:006033310.9HLA-DQA1, HLA-DQB1, HLA-DRB1
11chemical synaptic transmissionGO:000726810.9ATXN3, HCRT, HCRTR1, HCRTR2
12regulation of circadian sleep/wake cycle, sleepGO:004518710.9HCRTR1, HCRTR2
13neuropeptide signaling pathwayGO:000721810.8HCRT, HCRTR1, HCRTR2
14response to peptideGO:190165210.8HCRTR1, HCRTR2
15phospholipase C-activating G-protein coupled receptor signaling pathwayGO:000720010.8HCRT, HCRTR2, P2RY11
16immune responseGO:000695510.7HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFSF4
17T cell costimulationGO:003129510.3HLA-DQA1, HLA-DQB1, HLA-DRB1

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1orexin receptor activityGO:001649910.7HCRTR1, HCRTR2
2MHC class II receptor activityGO:003239510.7HLA-DQA1, HLA-DQB1, HLA-DRB1
3peptide antigen bindingGO:004260510.3HLA-DQA1, HLA-DQB1, HLA-DRB1

Sources for Narcolepsy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet